我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去）

- m6 }) p6 Y' M. u/ Y
6 f6 E- i3 K( V' d: V在淘宝上买了瓶澳洲产的蜂胶，还买了鱼跃指夹式血氧仪301，方便在家测定血氧和脉搏。
* |, p% E. q; w& C, Y) x

今天用指夹式血氧仪测了一下，老爸的血氧浓度是98%，心率是92.

血氧很好啊。
心律稍快。

7 `3 ^" c" ]. B7 w" o' ?0 N
后续可用药物：
1、白蛋白纳米紫杉醇
美国阿博利斯生物科学公司，ABRAXANE注射用紫杉醇（白蛋白结合型纳米微粒紫杉醇注射制剂）
  ]* U  L7 k% c7 l主要的副作用是：感觉神经病变，嗜中性白血球减少症,贫血，血小板减少。
% l1 ~# Q1 u. zAbraxane                    3/4 (514 pts)   Taxol     G3/4 (524 pts)
3 p5 ~! ]- u7 ~7 l* ^8 o感觉神经病变                   3/0                                  10/0
肌肉痛                             0/0                                 2/0
血小板减少                   13/4                                6/2
3 o, L$ z6 `1 p贫血                             22/5                                6/0
# B1 l% v; B$ P. D, x6 ]7 q& D3 B$ [
; |/ D3 R6 Z2 O1 g

国内医院价格：100mg一支，6000元。

8 f; f$ c- _5 Y$ S
4 R+ y, X3 S$ _  u  x
2066.78ae8061.Abraxane.pdf (151.65 KB, 下载次数: 44)

2012-1-5 14:34 上传

点击文件名下载附件

http://cancergrace.org/lung/2010 ... s-taxol-rr-results/
6 b. R& I0 g# K$ H& F2 ODr.West认为这药不值这个价，性价比太低。

; t9 F+ a  _4 X% I$ p/ a, I, l% ?SPARC (secreted protein acidic and rich in cysteine), 富含半胱氨酸的酸性分泌蛋白，是一种调节细胞外基质的糖蛋白,与某些基质成分、生长因子和细胞因子作用,参与组织重建、形态生成、细胞迁移和增殖,调节机体的生理和病理过程。
肿瘤分泌的SPARC蛋白，功能类似白蛋白受体，能专门吸引和粘附白蛋白。由于SPARC蛋白对白蛋白具有亲和力，因此SPARC蛋白能特异性地吸附紫杉醇白蛋白微粒，并把它聚集在肿瘤细胞上。

6 t+ M2 o! ?/ ^, K

6 Z2 g4 s3 ?% r; a: S& ^
3 j' x' ]# c% J5 y6 y2 I天气冷，没有去医院查肿瘤指标和检查肝肾功能。
- X& Q3 T, e) c/ k# D0 }前天去超市买米，抗米上楼，搞的气喘吁吁的，上楼一测心跳，140下，血氧降到90%以下，马上吸氧，才缓过劲来。
最近还是有轻微腹泻，皮肤干燥，掉了很多皮屑，不肯涂扶肤霜。
虫草吃完了，灵芝还有一些，不想吃了，还在喝黄芪水，吃海参，蜂胶，打胸腺法新（和日）。

老马回家休假了？
你爸爸抗米上楼？ 不会吧？

对啊。没有电梯的住宅小区。我还没有去看呢。电话里知道的。

老马 发表于 2012-1-9 00:02

7 i: o- S6 m& i, g2 L$ [) I                               
登录/注册后可看大图

对啊。没有电梯的住宅小区。我还没有去看呢。电话里知道的。

5 G, z" c& [# E% x0 S: }唉，我估计就10斤米吧。不可能是20斤的米。

2 U; W; s- u5 v. L) z% e4 _3 u现在有个疑问，卡铂的说明书说禁用于出血性肿瘤，出血并发症发生率为5%。
" c# ]* @$ m  f& s( G/ c2 }

阿瓦斯丁治疗肺鳞癌的安全性
7 U- h6 s% ]5 V; t4 W$ y. O( }% k贝伐单抗最严重的不良反应是肿瘤相关性出血，与鳞状细胞癌、肿瘤坏死、空洞形成及肿瘤靠近大血管有关，并可引起高血压等心向管不息反应。
$ K$ ?3 U, t: p; R! b
BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab (BV) plus paclitaxel/carboplatin (PC) as first-line treatment (tx) for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC).
Background: In a phase II study of first-line tx with BV + PC for NSCLC, squamous histology was found to be a risk factor for severe (Gr ≥ 3) pulmonary hemorrhage (PH). Subsequently, pts with predominantly squamous histology were generally excluded from phase III studies. This final analysis from the BRIDGE study assesses safety of delayed BV administration in pts with locally advanced or metastatic squamous NSCLC. Methods: BRIDGE was an open-label, single-arm, multicenter pilot study of PC alone in cycles 1 and 2, and PC + BV in cycles 3 to 6, followed by BV until progressive disease (PD) or unacceptable toxicity. Eligible pts had stage IIIb (with pleural effusion), stage IV, or recurrent squamous NSCLC. Pts with recent arterial thromboembolic events, gastrointestinal perforation, hemoptysis, untreated brain metastases, intrathoracic lesion(s) with cavitation, or anticoagulation therapy were not eligible. The primary endpoint was incidence of Gr ≥ 3 PH. Results: Forty- seven pts received 2 initial cycles of PC, and 31 continued on study to receive ≥ 1 dose of BV. Median age was 65 (range: 48-80); 96.3% had Stage IV disease. Pts received a median of 6.0 (range, 1-18) doses of BV, and 2 pts (6.5%) completed 12 mos of tx. Among the 31 pts who received BV, there were 3 reports of PH of any grade in 2 pts. One pt had Gr 1 PH during cycle 3, withdrew due to PD on the same day, and recovered from PH. A second pt developed Gr 3 PH after post-progression treatment, 44 days after the last BV dose; PH resolved 2 d later, but after another 55 d the pt developed Gr 4 PH, and subsequently died due to PD. Incidence of Gr ≥ 3 PH (1 pt) was 3.2% (90% CI: 0.3-13.5%). Nine pts (29.0%) experienced Gr 3 events, including 5 (16.1%) with hypertension; 5 experienced Gr 4 events (dyspnea, PH, basal ganglia infarction, cerebral ischemia and pain). Median progression-free survival (PFS) was 6.2 mos (95% CI: 5.32-7.62 mos); 57% of pts had PFS of ≥ 6 mos. Conclusions: The incidence of Gr ≥ 3 PH in this study was 3.2% (1 pt). No new safety signals were identified. Until further trials are conducted, tx of squamous NSCLC with BV should be considered experimental.

Microsoft Word - 阿瓦斯丁™_AVASTIN_中文说明书.pdf (242.23 KB, 下载次数: 150)

2012-1-18 09:42 上传

点击文件名下载附件